

Rheumatology Referral Form

****Please Attach Copy of Insurance Cards (Front & Back)****

Last Name:	First Name:	DOB:	Practice:
Address:			Address:
City:	State:	Zip:	City: State: Zip:
Phone:	SSN:		Prescriber Name:
Insurance Information			Prescriber NPI:
Insurance Plan:	Insurance Plan:	Nurse/Key Contact:	
Policy #	Policy #	Phone:	Fax:
Plan I.D. #	Plan I.D. #	Email:	

Diagnosis and Clinical Information

****Please Attach Clinical/Progress Notes, Labs, Test, Supporting Primary Diagnosis****

☐ Rheumatoid Arthritis	☐ Lupus Erythematosus	TB/PPD Test: ☐ Positive ☐ Negative Date _____
☐ Ankylosing Spondylitis	☐ Arthritic Psoriasis	Hep. B ☐ Positive ☐ Negative Date _____
☐ Gout		Allergies: _____
☐ Other: _____		
ICD-10: _____		
Currently received and/or prior failed therapies: _____		☐ NKDA
		Height: _____ Weight: _____
Length of treatment: _____		Treatment location: ☐ Home ☐ Infusion suite
Reason for discontinuation: _____		☐ Other _____

Nursing Orders

- ☐ Skilled nurse to assess and administer and/or teach self-administration where appropriate. Nurse to provide ongoing support as needed x 1 year.

Prescription Information

Medication	Dose/Strength	Directions
☐ Remicade (infliximab)	☐ 100mg vial	☐ INITIAL: Infuse _____ mg/kg IV over 2-3 hours at week 0, 2, 6 then every 8 weeks thereafter ☐ MAINTENANCE: Infuse _____ mg/kg IV over 2-3 hours every _____ weeks
☐ Stelara (ustekinumab)	☐ 45mg vial	☐ INITIAL: 45mg subcutaneously initially, 4 weeks later, followed by 45mg every 12 weeks ☐ MAINTENANCE: 45mg subcutaneously every 12 weeks ☐ INITIAL: 90mg subcutaneously initially, 4 weeks later, followed by 90mg every 12 weeks ☐ MAINTENANCE: 90mg subcutaneously every 12 weeks
☐ Simponi (golimumab) ARIA	☐ 50mg vial	☐ INITIAL: 2mg/kg IV at weeks 0, 4, and then every 8 weeks ☐ MAINTENANCE: 2mg/kg IV every 8 weeks
☐ Cimzia (certolizumab)	☐ 200mg vial	☐ INITIAL: 400mg subcutaneously at weeks 0, 2, and 4 weeks ☐ MAINTENANCE: 200 mg subcutaneously every 2 weeks ☐ MAINTENANCE: 400 mg subcutaneously every 4 weeks
☐ Cosentyx (secukinumab)	☐ Vial ☐ Prefilled syringe ☐ UnoReady pen	☐ INITIAL: Infuse 6mg/kg IV at week 0 as loading dose ☐ MAINTENANCE: 1.75mg/kg IV every 4 weeks (max maintenance dose 300mg per infusion) ☐ INITIAL: Inject 150mg or 300mg subcutaneously (circle corresponding dose) at weeks 0, 1, 2, 3, and 4. ☐ MAINTENANCE: 150mg or 300mg subcutaneously (circle corresponding dose) every 4 weeks
☐ Orencia (abatacept)	☐ 250mg vial	☐ INITIAL: _____ mg IV Frequency ☐ Every 4 weeks OR ☐ 0, 2, 4 weeks and every 4 weeks thereafter
☐ Krystexxa (pegloticase)	☐ 8mg	☐ Infuse 8mg IV over 2 hours every 2 weeks
☐ Tremfya (guselkumab)	☐ 100mg/mL prefilled syringe	☐ INITIAL: 100mg subcutaneously at week 0 and 4 ☐ MAINTENANCE: 100mg subcutaneously every 8 weeks thereafter

Continued on next page.

Prescription Information, continued

Medication	Dose/Strength	Directions
IVIg ☐ Brand _____ ☐ Substitution okay	☐ 0.4gm/kg ☐ 1gm/kg ☐ 2gm/kg ☐ Other: _____	☐ Daily x _____ day(s) ☐ Repeat every _____ week(s) x _____ cycles ☐ Other _____
SCIg ☐ Brand _____ ☐ Substitution okay	☐ _____gram(s) ☐ _____mg per kg ☐ _____grams/kg	☐ Once weekly ☐ Every 2 weeks ☐ Other frequency: _____ ☐ Where clinically appropriate, round to the nearest vial size.
☐ Rituxan (rituximab)	☐ 1000mg ☐ Other: _____	☐ Dose for RA in combination with methotrexate: two 1,000mg intravenous infusions separated by 2 weeks (one course) every 24 weeks - or based on clinical evaluation, but not sooner than every 16 weeks. Methylprednisolone 100mg intravenous or equivalent glucocorticoid is recommended 30 minutes prior to each infusion.
☐ Other		

Pre-Medication and Other Medications

* Infusion supplies as per protocol

* Anaphylaxis kit as per protocol

☐ Acetaminophen _____ mg PO prior to infusion

☐ Diphenhydramine
☐ _____ mg PO or ☐ _____ mL IV prior to infusion

☐ 0.9% NaCl for hydration
 _____ mL IV ☐ before ☐ after medication

☐ Other _____

Flush Protocol

– NaCl 0.9% 10mL

– Before and after infusion

I authorize Vital Care Infusion Services LLC and its representatives to initiate any insurance prior authorization process that is required for this prescription and for any future refills of the same prescription for the patient listed above which I order. I understand that I can revoke this designation at any time by providing written notice to Vital Care.

Physician Signature: _____

Date: _____

PRESCRIBER MUST MANUALLY SIGN - STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED

The attached document(s) contain confidential information which may be considered to be Protected Health Information and therefore required to be maintained as private and secure under HIPAA. The documents may also contain information which is otherwise considered to be privileged under state and federal laws. This communication is for the intended recipient only. If you are not the intended recipient, or a person responsible for delivering this communication to the intended recipient, you are prohibited from viewing, copying and/or distributing the information contained herein. Unlawful disclosure of the information attached may subject you to monetary penalties and sanctions. If you have received this communication in error, you should notify the sender immediately and thereafter permanently destroy all copies of this document in its entirety.

This form is not considered an order or prescription for medical services and/or supplies unless and until it is formally authorized by a healthcare provider in compliance with applicable laws and regulations.

This is not a valid prescription in the state of Arizona.